Objective: To investigate if a central cholinesterase inhibitor will reduce falling frequency in subjects with Parkinson disease (PD) with advanced postural instability.
ment for patients. Physical therapy with balance rehabilitation remains a mainstay of treatment but more options are needed.
We hypothesized that increasing central acetylcholine could improve balance and reduce falls in subjects with PD. It is known that medications with anticholinergic properties are associated with impaired balance, increased falls, and increased rates of bony fractures in the elderly. [6] [7] [8] [9] [10] PD itself can be considered an acetylcholine-deficient state based on cholinergic cell loss in the nucleus basalis of Meynert (NBM) and in the pedunculopontine nucleus (PPN)-laterodorsal tegmental complex. [11] [12] [13] Loss of PPN cells may be correlated with increasing balance impairment and disability as reflected in Hoehn & Yahr scores. 14 Furthermore, cholinergic forebrain projections (from NBM) are important in maintenance of normal cognition, and dementia is associated with increased risk of falling. 15 Thus, we initiated a controlled trial of an acetylcholinesterase inhibitor, donepezil (Aricept, Pfizer, New York, NY), in subjects with PD who fall frequently.
METHODS Standard protocol approvals, registrations, and patient consents. This trial (NCT00912808 in ClinicalTrials.gov) was approved by the Oregon Health & Sciences University (OHSU) Institutional Review Board and all subjects provided written informed consent for participation.
Design. The trial was a randomized, crossover, double-blind study of 15 weeks duration. Each drug phase, donepezil or identical placebo, lasted 6 weeks, with a 3-week washout period in between. In each drug phase, subjects were instructed to take 1 tablet (5 mg of donepezil or placebo) for 3 weeks and to increase to 2 tablets (10 mg) for the remaining 3 weeks. Drug and placebo tablets were identical in appearance and were provided by Pfizer. If intolerable side effects occurred during titration, the dose was halved until the effect abated and the titration schedule was resumed, or the subject chose to withdraw.
Subjects.
Eligible adult subjects were those diagnosed with probable idiopathic PD, defined as manifesting 2 of 3 cardinal features (tremor, rigidity, bradykinesia), without any other historical or physical signs to suggest another diagnosis, and were recruited from the OHSU Movement Disorders Clinic. All subjects were responsive to levodopa replacement therapy. The inclusion criterion specified a baseline frequency of falling or nearly falling 2 or more times per week. A fall was defined as an event which results in a person coming to rest inadvertently on the ground or other lower level, and other than a consequence of the following: sustaining a violent blow, loss of consciousness, sudden onset of paralysis, as in a stroke or an epileptic seizure. A near fall was defined as an involuntary or uncontrolled descent where the potential for a fall existed but the outcome was not a fall. All subjects were ambulatory about the home either inde-pendently or with a walker or cane, thus Hoehn & Yahr stage 5 excluded participation in the trial.
Subjects were excluded if they had freezing or non-CNS contributors to falls such as orthostasis, arthritic impairments, or neuropathy, and if subjects were currently using cholinesterase inhibitors or drugs with anticholinergic or sedative-hypnotic properties. Subjects were also excluded if they had a Folstein score Ͻ25 or unstable medical or psychiatric problems.
Measurements. The primary outcomes were fall and near-fall frequency determined using daily event recording by the subjects onto postcards which accumulated data for 1 week of monitoring, and collected for 6 weeks per phase. Postcards were mailed back to the investigator weekly. Secondary outcomes included change from baseline scores in each of the following scales during each phase.
1. Subject-completed global impression of improvement: a 7-point scale that is completed by the subject to indicate treatment response. This scale is anchored at 4 (no change), with 1 indicating very much improved; 2, much improved; 3, minimally improved. Conversely, 5 indicates minimally worse; 6, much worse; or 7, very much worse. 2. The Activities of Balance Confidence Scale 16 : measures confidence that respondents will not lose their balance or become unsteady in the course of 16 activities of daily living. Each item is self-rated from 0% (no confidence) to 100% (complete confidence) and in a previous study, patients with PD scored a mean of 68.7% Ϯ 2.9% compared with healthy controls who on average scored 93.2% Ϯ 1.3%. 17 3. The Berg Balance Scale 18 : composed of 14 tasks that assess balance such as sitting to standing, standing unsupported, standing with feet together, retrieving an object from the floor, and standing on one foot. In most items, the subject is asked to maintain a given position for a specific time. Points are lost if time or distance requirements are not achieved, or if external support or assistance from the examiner is needed (maximum score is 56).
Motor Unified Parkinson's Disease Rating Scale (UPDRS)
(part III): one section from a comprehensive evaluation of parkinsonism, and consists of rating the severity of the motor signs by clinical observation. Fourteen items including speech, hand movements, leg agility, posture, gait, and upright stability are rated using a 5-point scale with 0 ϭ normal or no deficits to 4 ϭ highest severity of abnormality. The scores in this section can vary from 0 to a total of 108. 19 : this is a 30-point questionnaire that estimates the severity of cognitive impairment using questions or tasks to assess mathematical, memory, and orientation abilities, with scores ranging from 0 to 30 (no errors).
Folstein Mini-Mental State Examination (MMSE)
Analysis. Means and standard deviations were calculated to describe the subject baseline characteristics. Paired t tests evaluated the difference between baseline and end of treatment frequency of falls. Changes posttreatment from baseline in secondary measures were also compared between the donepezil and placebo phases with paired t tests or Wilcoxon signed rank tests when data were nonparametric. SPSS was used for the analysis.
RESULTS
A total of 26 subjects were screened; 3 were not randomized due to failing inclusion/exclusion criteria. For subjects with intolerable adverse events during drug titration phase, the dose was halved until the adverse effects abated and the titration schedule was resumed. Four dropped out before the second phase (2 on active drug, 1 each during placebo phase and washout) and were excluded from the analysis. Two additional subjects withdrew before the end of the second crossover period, but were included in the analysis, leaving 19 subjects in whom the primary outcomes were measured (figure 1). 2, table) . The 5 subjects with the most frequent falls (at least 3 per week) showed the most reduction after 6 weeks on donepezil. Those on drug did not differ in near falls when compared to those on placebo; however, the 2 participants with the There was a trend toward improvement in subject-scored global impression of change with ϩ1.07 on donepezil and ϩ0.07 on placebo. However, there were no differences between the placebo or donepezil treatment in the change from baseline in the Activities of Balance Confidence Scale, Berg Balance Scale, UPDRS III, or Folstein MMSE scores (table) .
Of the 4 subjects who dropped out before phase II, 3 did so because of side effects of the study medi-cation (2 on donepezil due to insomnia, nausea; 1 on placebo due to increased tremor). One subject on active drug during the first phase worsened during the washout and refused to submit to the second phase. Side effects such as nausea, abnormal sweating, insomnia, headache, poor appetite, or weight loss were noted in 35% on donepezil, but were mild or transient in most. Interestingly, no fractures or other serious adverse events occurred during the course of this study despite nearly 200 falls. DISCUSSION Donepezil reduced fall frequency in frequently falling subjects with PD by approximately half (from 0.25 to 0.13 falls per day). Subjects who fell the most often at baseline demonstrated the most improvement, perhaps related to a floor effect; subjects with fewer falls had less room for improvement given the short duration of the study. Subjects who had deep brain stimulators appeared to respond as well as those treated medically, although the small number of subjects with DBS prevented subgroup analysis.
The reason that near falls were not affected by donepezil is unclear. One explanation may be that the working definition for near falls was ineffective in practice; near falls may be too subjective for subjects to accurately assess and remember. Perhaps the lack of reduction in near falls with donepezil treatment suggests that subjects are better able to recover from postural perturbations such that falls are avoided (i.e., would-be falls become only near falls). Another possibility is that a near fall is a different phenomenon, affected differently by adding acetylcholine to the CNS, than is a fall.
Our secondary outcomes do not suggest the etiology of the benefits of donepezil. The Berg Balance test did not reveal improvement in measures of balance. The subjects' balance confidence did not improve. The motor UPDRS did not suggest changes in the parkinsonism and MMSE did not indicate changes in cognition. The lack of change in secondary measures of balance, PD symptoms, and mental status could be due to lack of sensitivity of these clinical measures 5 or because falls were reduced for other reasons not tested. For example, patients with PD have impaired postural responses to external perturbations that are not improved with levodopa. 20 Improvement in automatic postural responses may not be detected with our secondary measures. 21 Why should donepezil improve falls? A strong rationale for this study was the evidence that drugs with anticholinergic properties are associated with falls. A review of several studies in other patient groups have documented that anticholinergics are associated with increased falls in the communitydwelling elderly or hospitalized patients. 6-10
Figure 2
Fall frequency is reduced during donepezil use
The effect appears to be more pronounced in those with higher rates of falling. By what mechanisms might augmentation of cholinergic neurotransmission reduce falls? First, the cortical projections from the cholinergic nucleus basalis of Meynert are heavily damaged in PD. 11 The nucleus basalis of Meynert has been implicated to be important for cognition and attentional processes. 22, 23 The role of optimal cognitive input in the success of balance maintenance and avoidance of falls is becoming increasingly apparent. 24 While it is recognized that cognitive deficits and falling are associated, the cause is difficult to infer. It could be postulated that attentional processes to the surrounding environment are important to maintenance of balance and avoidance of falls. Impaired attentional processes have been described in PD 25, 26 and attentional processes may be affected significantly by cholinergic manipulation. 27, 28 Our tests did not examine frontal executive function and attention, which may have yielded clues about the importance of these processes in fall reduction.
While attentional processes may have been improved with supplemental acetylcholine, structures mediating balance and upright stability must also be considered. The cerebellum influences balance, posture, and muscle tone as well as coordination of movement. Recent studies suggest that cholinergic input is important to the cerebellum, 29, 30 and may involve cholinergic projections from the PPN, the lateral paragigantocellular nucleus, and other smaller nuclei. 31 Preliminary animal evidence suggests that cholinergic input to Purkinje cells is important for optimal vestibular righting reflexes 32 and modulation of oculomotor reflexes. 33 Other human studies have suggested the archicerebellum is affected by acetylcholine and levels may decline with aging. 34 In PD, the degeneration of the PPN and locus coeruleus and loss of their projections to the cerebellum may account for at least some of the balance abnormalities that are a source of significant disability for many.
The PPN cholinergic projections include not only deep cerebellar nuclei, but also thalamic nuclei, the substantial nigra pars compacta, the subthalamic nucleus, and the globus pallidus interna. 35 Descending projections also include several midbrain, pontine, and medullary areas as well as the spinal cord. 36 A role for the PPN in gait and postural stability has been suggested by animal studies and in humans using deep brain stimulation though results are not conclusive. 37 However, it is likely that cholinergic supplementation affects not only cortical areas important for balance, but also throughout the neuraxis based on projections from the PPN that may play an important role in the maintenance of posture, balance, and gait. It is noteworthy that in a recent PET investigation of acetylcholinesterase activity in sub-jects with PD, a history of falling was associated with thalamic cholinergic hypofunction, likely due to PPN degeneration. 38 The limitations of this study include the small number of subjects and lack of objective measurement to quantify falls. One difficulty in conducting this trial was screening for subjects with PD with postural instability that could not be associated with proprioceptive loss in the feet, arthritic foot conditions, and orthostasis, common in the elderly. The most difficult condition to exclude was coexisting freezing of gait. In this study, 2 subjects who claimed to experience infrequent freezing and did not demonstrate significant freezing during screening manifested moderately severe ON gait freezing during subsequent study visits. These 2 subjects did not benefit from donepezil in fall reduction.
While overall fall frequency declined on drug, there were clearly some subjects who did not improve. Understanding the differences between responders and nonresponders may help us further understand causes of postural instability. Future investigations of these findings should include larger studies and ideally, objective measures. The possibility of improved cognition can be explored further with more detailed psychometric testing. Testing the components of postural control with computerized dynamic posturography may better illuminate the mechanisms for fall reduction. 39 Cholinesterase inhibitors have been used to treat cognitive decline in subjects with PD and have been tolerated well by the majority. 40 Reduced falls may be another reason to initiate this therapy but further studies are needed.
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